Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Journal of Probability and Statistics ; 2022, 2022.
Article in English | ProQuest Central | ID: covidwho-2020486

ABSTRACT

This manuscript considers some improved combined and separate classes of estimators of population mean using bivariate auxiliary information under stratified simple random sampling. The expressions of bias and mean square error of the proposed classes of estimators are determined to the first order of approximation. It is exhibited that under some particular conditions, the proposed classes of estimators dominate the existing prominent estimators. The theoretical findings are supported by a simulation study performed over a hypothetically generated population.

2.
In Silico Pharmacol ; 10(1): 12, 2022.
Article in English | MEDLINE | ID: covidwho-1959193

ABSTRACT

Despite the availability of COVID-19 vaccines, additional more potent vaccines are still required against the emerging variations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the present investigation, we have identified a promising vaccine candidate against the Omicron (B.1.1.529) using immunoinformatics approaches. Various available tools like, the Immune Epitope Database server resource, and NetCTL-1.2, have been used for the identification of the promising T-cell and B-cell epitopes. The molecular docking was performed to check the interaction of TLR-3 receptors and validated 3D model of vaccine candidate. The codon optimization was done followed by cloning using SnapGene. Finally, In-silico immune simulation profile was also checked. The identified T-cell and B-cell epitopes have been selected based on their antigenicity (VaxiJen v2.0) and, allergenicity (AllerTOP v2.0). The identified epitopes with antigenic and non-allergenic properties were fused with the specific peptide linkers. In addition, the 3D model was constructed by the PHYRE2 server and validated using ProSA-web. The validated 3D model was further docked with the Toll-like receptor 3 (TLR3) and showed good interaction with the amino acids which indicate a promising vaccine candidate against the Omicron variant of SARS-CoV-2. Finally, the codon optimization, In-silico cloning and immune simulation profile was found to be satisfactory. Overall, the designed vaccine candidate has a potential against variant of SARS-Cov-2. However, further experimental studies are required to confirm.

3.
Atna Journal of Tourism Studies ; 17(2), 2022.
Article in English | ProQuest Central | ID: covidwho-1939936

ABSTRACT

The purpose of the study was to have a better clarification of the popular themes studied by Indian researchers during the period 2000 to 2021. The paper helped in identifying the trends and development in research area in context to Indian Hospitality and tourism sector. The study selected a total of 1821 research papers of Indian origin from the scopus database during a span of 22 years (2000-2021). The selected publications were analyzed using different bibliometric methods of analysis using biblioshiny and VOS viewer within the scope of several parameters. The complete time period was divided into three distinct timeframes to study the research trends during the period. The maximum number of articles published in recent years, i.e. 2020, while minimum article publications in 2001. 1241 citations received in 2019 while only 110 citations received in 2005. 'Worldwide Hospitality and Tourism Themes' and 'International Journal of Contemporary Hospitality Management' were found to be the most productive journals. While ‘Singh S.’ is the most productive authors with a maximum number of articles, while 'Jauhari V' has the most number of citations for his work. Sustainability and conservation are the themes of common interest irrespective of timeframe, while the role of social media, covid 19 are recent trending topics for researchers. The study does contain certain limitations despite contributing significantly to the Hospitality and tourism literature in Indian context. The present study did not included publications other than articles like conferences proceedings, book chapters and dissertations etc. Selection of tools used and the keywords chosen for the study also limit the outcome. The findings of the analysis is helpful in better understanding the direction of research themes in the hotel and tourism industries. Evaluation of prominent authors and their work again helps on focusing the trending themes in the sector among researchers. Furthermore it helps future researchers in identifying key issues in the field of hospitality and tourism. The sample for this study, to the best of the authors' knowledge, was the most comprehensive collection of articles published in India's hospitality and tourism industries. This study adds substantially to the existing literature by highlighting current research orientations and trends in hospitality and tourism.

4.
Clin Epidemiol Glob Health ; 16: 101097, 2022.
Article in English | MEDLINE | ID: covidwho-1914208

ABSTRACT

Background: Colchicine is well known drug for the treatment of acute gout. Recently, it has also been used in the management of COVID-19 patients. Aim: The aim of current study is to find out the role of colchicine in COVID-19 patients. Material & methods: The relevant studies were searched in PubMed/Medline, Google scholar and clinical trail.gov.com till inception and sorted based on the inclusion and exclusion criteria. The quality assessment of studies were done using Newcastle Ottawa Quality Assessment Scale. The pooled estimate was calculated as odd ratio and pooled prevalence with 95% confidence interval. A random effect model was used and publication bias was assessed qualitatively by trim and fill method. Results: Out of 38 studies, a total of 6 studies were found relevant for the analysis containing 1146 patients (705 males and 441 females). The pooled odd ratio was found to be 0.35 [0.23, 0.53] which indicate significance reduction of mortality in colchicine group as compared to non-colchicine group. The pooled prevalence of the patients treated with colchicine were found to be significant [0.11(0.03, 0.24)]. The heterogeneity among studies was also found to be low (I2 = 11%). However, funnel plot has indicated the involvement of publication bias [Egger: bias = 10.168291 (95% CI = 5.042044 to 15.294537) P = 0.0053]. Conclusion: Colchicine might be helpful in reduction of mortality in the management of COVID-19 patients. However, further studies are required to confirm its exact role.

5.
Financ Res Lett ; 47: 102707, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1878165

ABSTRACT

We test the suitability of Gold and Bitcoin as safe-haven instruments in the backdrop of the Covid-19 related equity market meltdown by implementing the newly proposed Wavelet Quantile Correlation. We employ daily returns of Bitcoin, Gold, DJIA, CAC40, NSE50, S&P 500, NASDAQ, and EUROSTOXX from 05-01-2015 to 31-12-2020. Our results show that Gold consistently exhibits safe haven properties for all the markets except NSE in the long and short run, while Bitcoin provided mixed results. We find that Gold can act as an effective hedge and diversifier as well.

6.
Curr Hypertens Rev ; 2022 Apr 07.
Article in English | MEDLINE | ID: covidwho-1785252

ABSTRACT

The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], which indicates that there is no association between ACEI/ARB and the mortality rate of COVID-19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.

8.
Eur J Pharmacol ; 914: 174579, 2022 Jan 05.
Article in English | MEDLINE | ID: covidwho-1471963

ABSTRACT

BACKGROUND: Emerging reports have shown the benefits of steroids in hospitalized COVID-19 patients as life-saving drugs. However, the use of steroids in COVID-19 patients is confusing among many physicians. AIM: The aim of the current study was to find out the exact association of steroids in the deaths of COVID-19 patients. METHODS: The relevant studies were searched in PubMed, Google scholar, and Clinical trials registries till May 25, 2021 and sorted out based on inclusion and exclusion criteria. The quality of studies was assessed using a standard scale. The pooled odds ratio was calculated with a 95% confidence interval. The sensitivity and sub-group analyses were also done. The publication bias was assessed qualitatively. The Rev Man 5 was used for all analyses with a random-effect model. RESULTS: The quantitative analysis was done with 9922 patients (6265-male and 3657-females) from 21 relevant studies. The pooled estimate results i.e. 0.52 [0.34, 0.80] have shown a significant reduction in deaths of COVID-19 patients in the steroidal group as compared to the non-steroidal group. The sensitivity analyses did not alter our conclusions. In subgroup analysis, methylprednisolone has shown a significant reduction in deaths of COVID-19 patients as compared to the non-steroidal group, however, more clinical evidence is required for dexamethasone and hydrocortisone. CONCLUSION: The use of steroids in hospitalized COVID-19 patients is useful to reduce deaths.


Subject(s)
COVID-19 , Methylprednisolone/therapeutic use , COVID-19/drug therapy , COVID-19/mortality , Humans , Mortality , SARS-CoV-2 , Steroids/classification , Steroids/therapeutic use
9.
Int J Clin Pract ; 75(11): e14515, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1341257

ABSTRACT

COVID-19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.


Subject(s)
COVID-19 , Respiratory Distress Syndrome , Aspirin/therapeutic use , Humans , SARS-CoV-2
10.
ACS Chem Neurosci ; 12(15): 2776-2797, 2021 08 04.
Article in English | MEDLINE | ID: covidwho-1309426

ABSTRACT

Common symptoms such as dizziness, headache, olfactory dysfunction, nausea, vomiting, etc. in COVID-19 patients have indicated the involvement of the nervous system. However, the exact association of the nervous system with COVID-19 infection is still unclear. Thus, we have conducted a meta-analysis of clinical studies associated with neurological problems in COVID-19 patients. We have searched for electronic databases with MeSH terms, and the studies for analysis were selected based on inclusion and exclusion criteria and quality assessment. The Stats Direct (version 3) was used for the analysis. The pooled prevalence with 95% confidence interval of various neurological manifestations reported in the COVID-19 patients was found to be headache 14.6% (12.2-17.2), fatigue 33.6% (29.5-37.8), olfactory dysfunction 26.4% (21.8-31.3), gustatory dysfunction 27.2% (22.3-32.3), vomiting 6.7% (5.5-8.0), nausea 9.8% (8.1-11.7), dizziness 6.7% (4.7-9.1), myalgia 21.4% (18.8-24.1), seizure 4.05% (2.5-5.8), cerebrovascular diseases 9.9% (6.8-13.4), sleep disorders 14.9% (1.9-36.8), altered mental status 17.1% (12.3-22.5), neuralgia 2.4% (0.8-4.7), arthralgia 19.9% (15.3-25.0), encephalopathy 23.5% (14.3-34.1), encephalitis 0.6% (0.2-1.3), malaise 38.3% (24.7-52.9), confusion 14.2% (6.9-23.5), movement disorders 5.2% (1.7-10.4), and Guillain-Barre syndrome 6.9% (2.3-13.7). However, the heterogeneity among studies was found to be high. Various neurological manifestations related to the central nervous system (CNS) and peripheral nervous system (PNS) are associated with COVID-19 patients.


Subject(s)
COVID-19 , Encephalitis , Guillain-Barre Syndrome , Nervous System Diseases , Headache/epidemiology , Headache/etiology , Humans , Nervous System Diseases/epidemiology , Nervous System Diseases/etiology , SARS-CoV-2
11.
Preprint in English | medRxiv | ID: ppmedrxiv-20221200

ABSTRACT

BackgroundCOVID-19 curve can be flattened by adopting mass screening protocols with aggressive testing and isolating infected populations. The current approach largely depends on RT-PCR/rapid antigen tests that require expert personnel resulting in higher costs and reduced testing frequency. Loss of smell is reported as a major symptom of COVID-19, however, a precise olfactory testing tool to identify COVID-19 patient is still lacking. MethodsTo quantitatively check for the loss of smell, we developed an odor strip, "COVID-Anosmia checker", spotted with gradients of coffee and lemon grass oil. We validated its efficiency in healthy and COVID-19 positive subjects. A trial screening to identify SARS-CoV-2 infected persons was also carried out to check the sensitivity and specificity of our screening tool. FindingsIt was observed that COVID positive participants were hyposmic instead of being anosmic when they were subjected to smelling higher odor concentration. Our tool identified 97% of symptomatic and 94% of asymptomatic COVID-19 positive subjects after excluding most confounding factors like concurrent chronic sinusitis. Further, it was possible to reliably predict COVID-19 infection by calculating a loss of smell score with 100% specificity. We coupled this tool with a mobile application, which takes the input response from the user, and can readily categorize the user in the appropriate risk groups. ConclusionLoss of smell can be used as a reliable marker for screening for COVID-19. Our tool can be used for first-line screening to trace out COVID-19 infection effectively. It can be used in difficult to reach geographical locations.

12.
Economics Bulletin ; 40(3):2005-+, 2020.
Article | Web of Science | ID: covidwho-777107

ABSTRACT

We test the safe-haven property of Gold and Bitcoin against equity markets (NSE50, DJIA, SSE, and CAC40) in the backdrop of Covid-19. We employ two multivariate volatility models, namely DCC and cDCC GARCH for analytical purposes. We find both Gold and Bitcoin to be negligibly correlated with equity returns most of the time. However, we observe a positive correlation during the initial phase of Covid-19. The results suggest that both Gold and Bitcoin exhibit the safe-haven property overall. However, during Covid-19, the safe-haven property of both Bitcoin and Gold is found to be partially compromised. We find Gold to exhibit relatively better safe-haven properties.

13.
Emergency Medicine News ; 42(5C), 2020.
Article | WHO COVID | ID: covidwho-275514
SELECTION OF CITATIONS
SEARCH DETAIL